EUVIMEDEUVIMED entdecken
Open Access

Distributional Cost-Effectiveness Analysis in Genomic Medicine: Considerations for Addressing Health Equity

Hadley Stevens Smith, James Buchanan, Ilias Goranitis, Maarten J IJzerman, Tara A Lavelle, Deborah A Marshall, Dean A Regier, Wendy J Ungar, Deirdre Weymann, Sarah Wordsworth, Kathryn A Phillips, Jeroen P Jansen

Value in Health · 2025

DOI: 10.1016/j.jval.2025.04.2162 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Value in Health, 2025. Verfasst von Hadley Stevens Smith und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Population Medicine, Harvard Medical School, Boston, MA, USA; Center for Bioethics, Harvard Medical School, Boston, MA, USA. Electronic…. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Health Equity, Genomics. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHGRI NIH HHS, National Institutes of Health, Canada Research Chairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Distributional cost-effectiveness analysis (DCEA) supports equitable resource allocation by quantifying equity-efficiency trade-offs. DCEA may be particularly useful to understand equity impacts in the context of genomic medicine, a rapidly growing clinical area that has prompted concerns about its potential to exacerbate health inequities by differentially benefitting some population groups over others because of disparities in research inclusion and access to specialty care. This article critically examines the application of DCEA in the context of genomic medicine. METHODS: We articulate steps for distributional impact assessment in the context of genomic medicine by adapting an existing conceptual framework for understanding the causal pathway between a healthcare intervention and the distribution of costs and effects among social groups, the inequality staircase. We discuss related data equity considerations and evidence requirements specific to genomic medicine interventions. RESULTS: The need for and receipt of a genomic medicine intervention, as well as an intervention's short-term and long-term effects, may vary across equity-relevant subgroups. Research to enhance the relevance of DCEA in genomic medicine should avoid conflation of biological and social factors, empower populations that are underrepresented in genomics research, accurately assess variation in outcomes across equity-relevant subgroups, and develop methods for incorporation of nonhealth outcomes within a DCEA framework. CONCLUSIONS: Best practice-aligned applications of DCEA may facilitate transparent discussions of health equity in coverage and implementation decisions. This article provides guidance to researchers on the use of DCEA in genomic medicine and other clinical areas with similarly complex considerations around equity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisHealth EquityGenomicsHumansHealthcare DisparitiesCost-Effectiveness Analysis

Stichwörter der Autor:innen

distributionalequityequity-efficiency trade-offsgenomic medicineprecision medicine

Autor:innen und Institutionen

  • Department of Population Medicine, Harvard Medical School, Boston, MA, USA; Center for Bioethics, Harvard Medical School, Boston, MA, USA. Electronic address: hadley_smith@hphci.harvard.edu.
  • Health Economics and Policy Research Unit, Center for Evaluation and Methods, Wolfson Institute of Population Health, Queen Mary University of London, London, England, UK; National Institute for Health Research, Barts B…
  • Economics of Genomics and Precision Medicine Unit, Center for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia; Australian Genomics, Murdoch Children's…
  • University of Melbourne Center for Cancer Research, Melbourne, VIC, Australia; Erasmus School of Health Policy and Management, Rotterdam, The Netherlands.
  • Center for the Evaluation of Value and Risk and Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
  • Cumming School of Medicine, Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Alberta Children's Hospital Research Institute, Calgary, Alberta, Canada.

Förderung

  • NHGRI NIH HHS
  • National Institutes of Health
  • Canada Research Chairs
  • National Human Genome Research Institute

Zitieren

APA

Smith, H. S., Buchanan, J., Goranitis, I., IJzerman, M. J., Lavelle, T. A., Marshall, D. A., Regier, D. A., Ungar, W. J., Weymann, D., Wordsworth, S., Phillips, K. A., & Jansen, J. P. (2025). Distributional Cost-Effectiveness Analysis in Genomic Medicine: Considerations for Addressing Health Equity. Value in Health. https://doi.org/10.1016/j.jval.2025.04.2162

Vancouver

Smith HS, Buchanan J, Goranitis I, IJzerman MJ, Lavelle TA, Marshall DA, et al. Distributional Cost-Effectiveness Analysis in Genomic Medicine: Considerations for Addressing Health Equity. Value in Health. 2025. doi:10.1016/j.jval.2025.04.2162

BibTeX
@article{Smith2025,
  author = {Smith, Hadley Stevens and Buchanan, James and Goranitis, Ilias and IJzerman, Maarten J and Lavelle, Tara A and Marshall, Deborah A and Regier, Dean A and Ungar, Wendy J and Weymann, Deirdre and Wordsworth, Sarah and Phillips, Kathryn A and Jansen, Jeroen P},
  title = {Distributional Cost-Effectiveness Analysis in Genomic Medicine: Considerations for Addressing Health Equity},
  journal = {Value in Health},
  year = {2025},
  doi = {10.1016/j.jval.2025.04.2162}
}
Kostenlos starten →